Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 645 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Biosimilar drugs: Current status

Kumar Rajiv, Singh Jagjit

Year : 2014| Volume: 4| Issue : 2 | Page no: 63-66

   This article has been cited by
1 Medical Students’ Knowledge and Awareness Levels about Biologics and Biosimilars: The Earlier the Better?
Devrim Demir-Dora,Zinnet Sevval Aksoyalp
Expert Opinion on Biological Therapy. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Close, but no cigar: Biosimilar products and firm regulatory stance
Julie Babyar
International Journal of Healthcare Management. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
3 Streptokinase: An Efficient Enzyme in Cardiac Medicine
Muhammad A. Zia
Protein & Peptide Letters. 2020; 27(2): 111
[Pubmed]  [Google Scholar] [DOI]
4 Similar biologics in India: A story of access or potential for compromise?
Ramesh Jois,Sukumar Mukherjee,S Rajeswari,PD Rath,Vishal Goyal,Disha Gupta
Indian Journal of Medical Research. 2020; 152(5): 456
[Pubmed]  [Google Scholar] [DOI]
5 Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab
Tabinda Saleem,Hafiz Qurashi,Munira Jamali,Janet Chan Gomez,Tejaswi Kanderi
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience
Sakshi Mittal,G. S. R. S. N. K. Naidu,Saket Jha,Manish Rathi,Ritambhra Nada,Ranjana W Minz,Kusum Sharma,Varun Dhir,Sanjay Jain,Aman Sharma
Clinical Rheumatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
7 Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis
Janine Griesser,Gergely Hetényi,Christoph Federer,Christian Steinbring,Helmut Ellemunter,Katharina Niedermayr,Andreas Bernkop-Schnürch
International Journal of Pharmaceutics. 2019; 557: 124
[Pubmed]  [Google Scholar] [DOI]
8 Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis
Ju-Yang Jung,Ji-Won Kim,Hyoun-Ah Kim,Chang-Hee Suh
Expert Opinion on Biological Therapy. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery
Kohei Miyata,Masami Ukawa,Kohta Mohri,Kozue Fujii,Mako Yamada,Sohei Tanishita,Satoshi Higashitarumi,Seiya Ishizaki,Hironori Kumagai,Kyohei Ochiai,Ken-ichiro Hiwatari,Kazufumi Tsubaki,Koichi Shigeno,Etsuo Tobita,Hideo Kobayashi,Shinji Sakuma
Bioconjugate Chemistry. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis
Imran H. Iftikhar,Mathew Schimmel,William Bender,Colin Swenson,David Amrol
Lung. 2018; 196(5): 517
[Pubmed]  [Google Scholar] [DOI]
11 Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region
Prasan Deep Rath,Der-Yuan Chen,Jieruo Gu,Vivian W. Y. Lee,Nizar Abdulateef Al Ani,Khalid Shirazy,Lyndon Llamado
International Journal of Rheumatic Diseases. 2018;
[Pubmed]  [Google Scholar] [DOI]
12 Protein biomarkers for subtyping breast cancer and implications for future research
Claudius Mueller,Amanda Haymond,Justin B. Davis,Alexa Williams,Virginia Espina
Expert Review of Proteomics. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
13 Personalized medicine with biologics for severe type 2 asthma: current status and future prospects
Marie Godar,Christophe Blanchetot,Hans de Haard,Bart N. Lambrecht,Guy Brusselle
mAbs. 2017; : 00
[Pubmed]  [Google Scholar] [DOI]
14 The road from development to approval: evaluating the body of evidence to confirm biosimilarity
Paul Declerck,Mourad Farouk Rezk
Rheumatology. 2017; 56(suppl_4): iv4
[Pubmed]  [Google Scholar] [DOI]
15 Large Molecule Pharmacotherapy
Patricia Anne O’Malley
Clinical Nurse Specialist. 2017; 31(3): 134
[Pubmed]  [Google Scholar] [DOI]
16 Improving Access to Cancer Treatments: The Role of Biosimilars
Rakesh Chopra,Gilberto Lopes
Journal of Global Oncology. 2017; 3(5): 596
[Pubmed]  [Google Scholar] [DOI]
17 Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality
David Brühlmann,Michael Sokolov,Alessandro Butté,Markus Sauer,Jürgen Hemberger,Jonathan Souquet,Hervé Broly,Martin Jordan
Biotechnology and Bioengineering. 2017;
[Pubmed]  [Google Scholar] [DOI]
18 Biosimilars in Germany: the emergence of a new industry in the light of the varieties of capitalism approach
Andreas Pyka,Tobias Buchmann,Ben Vermeulen
Technology Analysis & Strategic Management. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
19 Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Sara Francescon,Giulia Fornasier,Paolo Baldo
Oncology and Therapy. 2016;
[Pubmed]  [Google Scholar] [DOI]
20 Key strategic factors for stakeholders in the current global biosimilar market
Daniel Casey
Drug Discovery Today. 2016; 21(2): 208
[Pubmed]  [Google Scholar] [DOI]
21 Recent Advances in Application of Pharmacogenomics for Biotherapeutics
Pramod B. Mahajan
The AAPS Journal. 2016;
[Pubmed]  [Google Scholar] [DOI]
22 Fractal geometry as a new approach for proving nanosimilarity: A reflection note
Costas Demetzos,Natassa Pippa
International Journal of Pharmaceutics. 2015; 483(1-2): 1
[Pubmed]  [Google Scholar] [DOI]
23 Using simple models to describe the kinetics of growth, glucose consumption, and monoclonal antibody formation in naive and infliximab producer CHO cells
Julián López-Meza,Diana Araíz-Hernández,Leydi Maribel Carrillo-Cocom,Felipe López-Pacheco,María del Refugio Rocha-Pizaña,Mario Moisés Alvarez
Cytotechnology. 2015;
[Pubmed]  [Google Scholar] [DOI]


Read this article